Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.

[2][3][4] While its exact mechanism of action is not well characterized,[2] it is believed to be an NMDA receptor antagonist,[5][6] but also promoting the synthesis of dopamine.

[7][8] It is an hERG blocker and can produce long QT syndrome as a side effect.

[10][11] Budipine can be prepared from the 1-tert-butyl-4-piperidone [1465-76-5] directly by treatment with benzene in the presence triflic acid.

[12] This method of synthesis enables a 99% yield of product.